Oxytocin: what it is, what the nasal spray trials found and what the label says

Oxytocin is a peptide hormone with two well-established physical jobs: it contracts the uterus during labour and it drives the let-down of milk during breastfeeding. Vincent du Vigneaud’s laboratory worked out its amino acid sequence and proposed its structure in 1953 ^[1], and the synthetic peptide has been an obstetric drug for more than sixty years. The US Pitocin label describes it as a nonapeptide, meaning nine amino acids, standardised to 10 units per millilitre ^[2]; its formula is C43H66N12O12S2 and its molecular weight about 1007 g/mol ^[17].

The oxytocin hormone is also released inside the brain, where it acts on social and emotional circuits, and this is the source of its reputation as the love hormone. Animal research on pair bonding, maternal behaviour and social recognition led to a wave of human experiments from 2005 onwards in which the peptide was sprayed into the nose and behaviour measured. Those studies are the reason oxytocin nasal spray is sold by compounding pharmacies and research vendors, and they are examined below.

The licensed product and the online product are different things. Licensed oxytocin is a sterile solution for intravenous or intramuscular use in a maternity unit, with dosing determined minute by minute by the response of the uterus ^{[2] [3]}. Oxytocin sold online as a “research” nasal spray or a freeze-dried oxytocin peptide vial is not the licensed medicine and has no regulator behind it; see our guide to what research peptides are. Oxytocin is a close relative of vasopressin, and among the peptides on this site it is most often bought alongside PT-141, kisspeptin-10 and selank.

Oxytocin acts on a single receptor found in the smooth muscle of the uterus and the milk ducts, in the kidney, the heart and blood vessels, and in many brain regions. In the uterus at term, receptor numbers rise sharply, which is why a hormone that has little effect early in pregnancy becomes a powerful stimulant of contractions at the end of it. Given intravenously, the uterine response begins almost immediately and subsides within an hour of stopping; given into muscle it starts within three to five minutes and lasts two to three hours ^[2]. The plasma half-life is one to six minutes according to the US label ^[2] and three to twenty minutes according to the UK SmPC ^[3], with clearance by the liver and kidney.

Two other actions matter for safety. Oxytocin has an intrinsic antidiuretic effect, closely related to vasopressin’s, which makes the kidney retain water; the label warns of water intoxication when it is infused for long periods, particularly with oral fluids ^[2]. And a rapid intravenous bolus of several units can cause a short-lived drop in blood pressure with flushing and a reflex fast heart rate, which the UK SmPC says can cause myocardial ischaemia in people with existing heart disease, along with QT prolongation ^[3].

Whether intranasal oxytocin reaches the brain at all has been argued over for a decade. A 2016 critique in Biological Psychiatry noted that very little of the large amounts sprayed into the nose appears in cerebrospinal fluid, while blood levels rise to supraphysiological values with likely effects on the gut, heart and reproductive tract, and called for scepticism, preregistration and proper dose-response studies ^[6]. A 2021 review argued the other way, that converging human and animal evidence supports functionally relevant nose-to-brain delivery ^[7]. Both sides agree that the route, the dose and the timing are poorly standardised across the literature.

The oxytocin benefits people search for, trust, bonding, social confidence, libido, appetite control, rest on the intranasal literature. Its founding paper was published in Nature in 2005: in an economic trust game, participants who received intranasal oxytocin were more willing to hand money to a stranger than those who received placebo, an effect the authors attributed to increased willingness to accept social risk rather than to general risk-taking ^[4]. That study prompted hundreds more.

The problem is what came after. A 2016 statistical review concluded that intranasal oxytocin studies are generally underpowered, that pre-study odds and bias were unfavourable, and that there is a high probability that most published intranasal oxytocin findings do not represent true effects ^[5]. Later, larger and preregistered studies have tended to confirm that verdict, and the trust effect itself has proved difficult to replicate.

Autism is the best-tested clinical claim. A 2003 study of 15 adults found that an oxytocin infusion reduced repetitive behaviours compared with placebo ^[9], and a 2017 four-week trial in 32 children reported improved social responsiveness with 24 IU twice daily, but only when baseline oxytocin levels were included in the analysis, with the largest gains in children who started with the lowest levels ^[10]. The definitive test was SOARS-B, a 24-week, placebo-controlled trial in 290 children and adolescents aged 3 to 17 given a target dose of 48 IU a day. The primary social-withdrawal score improved by 3.7 points on oxytocin and 3.5 on placebo, a difference of 0.2 that was not significant; secondary outcomes generally did not differ; and adverse events were similar in the two groups ^[8]. The authors noted that oxytocin had already been given in clinical practice to many children with autism before the evidence was in.

Appetite and weight follow the same pattern. A single 24 IU dose reduced calorie intake at a test meal, with a preference for less fat, in 25 fasting healthy men ^[11], and in another laboratory study oxytocin cut snacking on chocolate cookies by 25% without affecting hunger-driven eating ^[12]. But when 61 adults with obesity took 24 IU four times a day for eight weeks in a randomised trial, weight change was 0.20 kg on oxytocin against 0.26 kg on placebo, with no benefit on body composition or energy expenditure, even though intake at a test meal was still lower ^[13]. Oxytocin for weight loss, in other words, changes a single meal in the laboratory and not body weight over two months.

Sexual function has been tested in women. In a 22-week crossover trial, 30 women with sexual dysfunction used 32 IU of intranasal oxytocin or placebo before intercourse for eight weeks each. Sexual function scores improved substantially in both arms (26% with oxytocin, 31% with placebo) with no significant difference between them ^[14]. We found no trial of oxytocin for men’s sexual function or of oxytocin for men’s mood or bonding outside the general social-behaviour literature.

In obstetrics the evidence base is large. The US label indicates Pitocin for induction of labour where there is a medical reason, for stimulating or reinforcing labour, as an adjunct in incomplete or inevitable abortion, and, after birth, to produce uterine contractions and control postpartum bleeding. It states plainly that Pitocin is not indicated for elective induction of labour, because the available data are inadequate to weigh benefits against risks ^[2]. The UK SmPC lists induction for medical reasons such as post-term pregnancy, ruptured membranes and pre-eclampsia, stimulation of labour in uterine inertia, use during caesarean section after delivery of the child, and prevention and treatment of postpartum haemorrhage ^[3].

A 2009 Cochrane review of 61 trials in 12,819 women found that, compared with waiting, intravenous oxytocin reduced the proportion of women who had not delivered vaginally within 24 hours from 53.8% to 8.4%, at the cost of more epidurals; compared with vaginal prostaglandins it was less effective at achieving delivery within 24 hours ^[16]. For preventing postpartum haemorrhage, a 2018 Cochrane network meta-analysis of 140 trials and 88,947 women found oxytocin, the WHO’s recommended drug, ranked behind ergometrine plus oxytocin, carbetocin and misoprostol plus oxytocin: about 10.5% of women given oxytocin alone had a haemorrhage of 500 mL or more, against 7.2% to 7.7% with the combinations ^[15]. These are trials of a hospital infusion in labour, and they say nothing about a nasal spray.

Intranasal oxytocin was once a licensed product (Syntocinon nasal spray, for milk let-down), but no nasal spray is licensed in the UK or US at the time of writing. The sprays sold today come from compounding pharmacies, which make them to order, or from research vendors, which do not.

Injected, within minutes: uterine contractions begin almost immediately after an intravenous dose and within three to five minutes of an intramuscular one ^[2]. In the intranasal experiments, testing typically began 30 to 45 minutes after the spray; the appetite study measured snack intake 45 minutes after dosing ^[12], and the trust study used a similar window ^[4]. Because the peptide is cleared within minutes, any effect of a single dose is short. The clinical trials that looked for lasting change over weeks, in autism and in obesity, did not find it ^{[8] [13]}.

Reported for information; none of this is a recommendation. For induction of labour, the US label says the dose is determined by the uterine response, must be individualised and must start at a very low level: the standard preparation is 10 units in 1,000 mL of saline, giving 10 milliunits per mL, run through an infusion pump ^[2]. The UK SmPC starts at 1 to 4 milliunits a minute and increases at intervals of no less than 20 minutes ^[3]. For postpartum bleeding, the US label describes 10 to 40 units added to a running infusion or 10 units into muscle after delivery of the placenta ^[2]. Water intoxication with convulsions is described at infusion rates of 40 to 50 milliunits a minute over long periods ^[2].

The intranasal research doses are a different scale. Single doses of 24 IU were used in the trust ^[4] and appetite ^[11] studies, 24 IU twice daily in the small autism trial ^[10], a target of 48 IU a day in SOARS-B ^[8], 24 IU four times daily for eight weeks in the obesity trial ^[13] and 32 IU before intercourse in the sexual function trial ^[14]. How much of a nasal dose is absorbed, and where it goes, is exactly what the two reviews above disagree about ^{[6] [7]}. The peptide calculator can convert an oxytocin vial labelled in milligrams into international units only if the vendor states the activity, which most do not; the licensed product is defined by biological units, not by mass.

Licensed oxytocin is an aqueous solution for intravenous infusion or intramuscular injection ^{[2] [3]}. The research literature uses nasal sprays, almost always from a compounding pharmacy or a manufacturer’s clinical-trial supply, and occasionally intravenous infusion ^[9]. Research vendors sell oxytocin acetate as a freeze-dried powder and as pre-made sprays. Oxytocin taken by mouth is broken down in the gut, and sublingual tablets and lozenges sold online have no published absorption data behind them.

The obstetric labels describe serious harms from a drug that acts on the uterus. The US label lists, in the mother, anaphylaxis, arrhythmias, postpartum haemorrhage, pelvic haematoma, subarachnoid haemorrhage, hypertensive episodes, rupture of the uterus and fatal afibrinogenaemia, and states that excessive dosage or hypersensitivity may result in uterine hypertonicity, spasm, tetanic contraction or rupture. Severe water intoxication with convulsions and coma has occurred with a slow infusion over 24 hours, and maternal death from oxytocin-induced water intoxication has been reported. In the fetus or newborn it lists bradycardia, low Apgar scores, jaundice, retinal haemorrhage and, from uterine overstimulation, hypoxia and death ^[2]. The UK SmPC adds hypotension, flushing, reflex tachycardia, myocardial ischaemia and QT prolongation after rapid intravenous bolus ^[3].

Intranasal oxytocin at research doses has looked benign in the trials that reported it: adverse events were similar to placebo in SOARS-B ^[8] and in the eight-week obesity trial, which recorded no serious adverse events ^[13]. That reassurance is limited to a few hundred people over weeks to months, at 24 to 48 IU a day, using pharmaceutical-grade spray. The 2016 critique’s point stands: nasal dosing produces supraphysiological blood levels with possible effects on the gut, heart and reproductive tract that the behavioural studies were not designed to detect ^[6].

Two specific cautions follow from the pharmacology. Oxytocin is contraindicated where uterine contraction is dangerous, so any use in pregnancy outside a maternity unit is hazardous. And its antidiuretic effect means large or repeated doses with high fluid intake can lower blood sodium ^[2]. Unregulated sprays and vials add the usual risks of an unlicensed product: unknown content, unknown sterility and, for a spray, unknown preservative.

Oxytocin is a prescription-only medicine in the UK (as generic oxytocin injection and Syntocinon), the US (Pitocin and generics), the EU and the other markets PepFinder covers. It is not a controlled drug in the UK, but supplying an unlicensed oxytocin product is a medicines offence, as explained on the UK legal status page. In the US, compounded nasal oxytocin is prepared under compounding rules rather than approved by the FDA, and products sold as research chemicals for human use fall under the rules on unapproved drugs described on the US legal status page. See the legal status overview for Canada, Australia and Europe.

Oxytocin is not named on the WADA Prohibited List ^[18], unlike the gonadotropins and growth hormone secretagogues on this site. A spray or vial sold as a research chemical is not a licensed medicine anywhere and is not covered by the obstetric safety data on this page.

The US Pitocin vials are stored at 20 °C to 25 °C ^[2]. The UK product is stored in a refrigerator at 2 °C to 8 °C, may be kept at up to 30 °C for three months and then discarded, and diluted infusions are used within 24 hours ^[3]. Oxytocin in solution is more fragile than the licensed room-temperature storage suggests, which is why the UK label refrigerates it. For freeze-dried research powder, the general rules in our guides to storing peptides and bacteriostatic water apply, and a spray bottle that has been open for weeks at room temperature should be assumed to have lost potency.

PepFinder does not sell oxytocin. To compare research vendors, see oxytocin prices, with UK and US listings. A nine-amino-acid peptide is easy to verify: a certificate of analysis should show a mass close to 1007 g/mol and an HPLC purity figure, and our guide to reading a peptide COA explains both. Sprays are harder, because the concentration per actuation and the preservative are what matter and few vendors state them. The third-party tested list shows which vendors publish independent results, and our guides to third-party peptide testing and spotting a fake peptide supplier cover the warning signs, of which “love hormone” marketing is one.